Skip to content

Microbiota Transplantation in Solid Organ Transplantation

Washed Microbiota Transplantation for Postoperative Complications in Solid Organ Transplantation

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06730451
Enrollment
50
Registered
2024-12-12
Start date
2018-01-01
Completion date
2028-12-31
Last updated
2024-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid Organ Transplant Complications

Keywords

Solid Organ Transplant Complications, Washed microbiota transplantation, Fecal microbiota transplantation, Diarrhea

Brief summary

Solid organ transplantation (SOT), an alternative therapy for end-stage diseases, offers increased longevity and better quantity of life. Posttransplant complications such as gastrointestinal symptoms, infection, and graft rejection increase risk with graft failure and death. However, the treatment of abovementioned complications remains unsatisfactory. Gut dysbiosis has been reported in patients with SOT, especially in patients with posttransplant complications. Recipients are more susceptible to gut dysbiosis as long-term use of immunosuppressants, antibiotics and corticosteroids. Restoring gut microbiome may be a promising therapy for posttransplant complications. Washed microbiota transplantation (WMT) is a newly improved methodology of fecal microbiota transplantation based on automatic facilities, washing process and a new delivery routine. In this study, investigators aimed to evaluate the efficacy and safety of WMT for postoperative complications in SOT.

Interventions

Washed microbiota suspension delivered through mild-gut and lower-gut

Sponsors

The Chinese fmtBank
CollaboratorUNKNOWN
The Second Hospital of Nanjing Medical University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1. solid organ transplantation recipients; 2. suffering from gastrointestinal symptoms (e.g. diarrhea, constipation, abdominal pian), infection (e.g. Clostridium difficile) post-transplantation and so on; 3. is willing to undergo WMT and provide written informed consent.

Exclusion criteria

1. patients with history of gastrointestinal diseases or homologous pathogen infection pre-transplant; 2. pregnant or lactating females; 3. expected survival\<1 months; 4. unable to understand the purpose of the study, communicate effectively with investigators and comply with all study procedures; 5. follow up less than 1-month post-WMT; 6. other conditions judged by investigators not suitable for study participation.

Design outcomes

Primary

MeasureTime frameDescription
Stool frequency and consistencyBaseline, 1-week, 2-week, 1-month, 2-month, 3-month post WMTStool frequency ≥3 times per day was considered as diarrhea. Higher frequency represents more severe diarrhea. Stool consistency will be evaluated according to the Bristol Stool Form Scale ranging from type 1 - type 7. Type 1 and 2 indicate constipation, Type 3 and type 4 indicate normal defecation, Type 5, 6 and 7 indicate diarrhea.
Gastrointestinal Symptom Rating Scale (GSRS)Baseline, 1-week, 2-week, 1-month, 2-month, 3-month post WMTGSRS is a 15-item instrument designed to assess the symptoms associated with common GI disorders. The GSRS consists of 5 subscales (reflux, diarrhea, constipation, abdominal pain, and indigestion) producing a mean subscale score ranging from 1 (no discomfort) to 7 (very severe discomfort).

Secondary

MeasureTime frameDescription
The changes in gut microbiota composition by sequencing faecal metagenomeBaseline, 1-month, 3-month post WMTThe changes in gut microbe composition before and after WMT were evaluated by sequencing faecal metagenome.
Quality of life by 36-Item Short Form Health Survey(SF-36)Baseline, 1-month, 3-month post WMTSF-36 is a 36-item questionnaire to assess the impact of disease on daily life. The SF-36 consists of 8 subscales (vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health) ranging from 0 to 100. Lower scores represent more dysfunction.

Countries

China

Contacts

Primary ContactFaming Zhang, PhD
fzhang@njmu.edu.cn086-25-58509883

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026